Cambrooke Therapeutics Expands Scope for Patients Impacted by Medical Nutrition Needs

AYER, Mass., Dec. 4, 2013 /PRNewswire/ -- Cambrooke Therapeutics announced today that the company has formally changed its name to reflect its broader focus on developing and offering therapeutic nutrition products for people with highly specialized, medically supervised diets. In conjunction with its expansion, Cambrooke Therapeutics is also launching a new web site at www.cambrooketherapeutics.com to provide information on medical nutrition and its work in the field.    

(Logo: http://photos.prnewswire.com/prnh/20131204/DC27415LOGO )

Cambrooke Therapeutics, formerly known as Cambrooke Foods, was founded in 2000 by David and Lynn Paolella, parents of children diagnosed with a rare metabolic disorder, Phenylketonuria (PKU). Today, Cambrooke is a leading global provider of therapeutic nutrition products, also known as medical foods, for patients with inborn errors of protein metabolism such as PKU and Maple Syrup Urine Disease. The company is an innovator in the field of PKU treatments, bringing to the market the only natural whole protein source (glycomacropeptide) for the dietary management of PKU through collaboration with the University of Wisconsin.

"As leading experts in the field of medical nutrition, we see increasing demand for therapeutic options for targeted patient populations," said Marc Tewey, chief executive officer at Cambrooke.  "Our skill and expertise in working with researchers, physicians and patients will enable us to drive the development of an expanded pipeline of medical nutrition products for a variety of conditions that will improve patients' lives."

The need for therapeutic nutrition products is growing as medical professionals seek non-drug options for patients. The development and commercialization of these products requires a highly specialized team with expertise in nutrition, food processing, formulation development and medical communication. Cambrooke partners with leading academic research facilities to create and test new therapeutic options. 

"We are committed to innovation and meeting the needs of patients who would otherwise have limited or no choice in treatment options," said Lynn Paolella, co-founder of Cambrooke. "We are going to take the skills and dedication that delivered on our success in PKU and use our core strength of working with academia to create commercially viable nutritional therapeutics based on medical science to help others."

Cambrooke Therapeutics is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products. Its medical food and low protein products are available in the United States, Spain, Portugal and Australia. More information is available at www.cambrooketherapeutics.com.

SOURCE Cambrooke Therapeutics